GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » BioSig Technologies Inc (NAS:BSGM) » Definitions » Beneish M-Score

BioSig Technologies (BioSig Technologies) Beneish M-Score : 0.97 (As of Apr. 25, 2024)


View and export this data going back to 2014. Start your Free Trial

What is BioSig Technologies Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 0.97 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for BioSig Technologies's Beneish M-Score or its related term are showing as below:

BSGM' s Beneish M-Score Range Over the Past 10 Years
Min: -4.56   Med: -1.8   Max: 0.97
Current: 0.97

During the past 11 years, the highest Beneish M-Score of BioSig Technologies was 0.97. The lowest was -4.56. And the median was -1.80.


BioSig Technologies Beneish M-Score Historical Data

The historical data trend for BioSig Technologies's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioSig Technologies Beneish M-Score Chart

BioSig Technologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -4.56 0.97

BioSig Technologies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.56 -3.59 -14.34 -16.35 0.97

Competitive Comparison of BioSig Technologies's Beneish M-Score

For the Medical Devices subindustry, BioSig Technologies's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioSig Technologies's Beneish M-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, BioSig Technologies's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where BioSig Technologies's Beneish M-Score falls into.



BioSig Technologies Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of BioSig Technologies for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 42.3697+0.528 * 0.8007+0.404 * 0.5087+0.892 * 0.0629+0.115 * 0.5913
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 17.15+4.679 * -6.418799-0.327 * 2.8843
=0.97

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $0.02 Mil.
Revenue was 0.012 + 0.001 + 0 + 0.005 = $0.02 Mil.
Gross Profit was 0.012 + 0.001 + 0 + 0.005 = $0.02 Mil.
Total Current Assets was $0.53 Mil.
Total Assets was $1.80 Mil.
Property, Plant and Equipment(Net PPE) was $0.94 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.36 Mil.
Selling, General, & Admin. Expense(SGA) was $23.08 Mil.
Total Current Liabilities was $4.58 Mil.
Long-Term Debt & Capital Lease Obligation was $0.10 Mil.
Net Income was -6.049 + -4.567 + -11.093 + -7.332 = $-29.04 Mil.
Non Operating Income was 0.038 + 0 + -0.225 + 0 = $-0.19 Mil.
Cash Flow from Operations was -2.942 + -3.828 + -4.895 + -5.648 = $-17.31 Mil.
Total Receivables was $0.01 Mil.
Revenue was 0.135 + 0.135 + 0.008 + 0.008 = $0.29 Mil.
Gross Profit was 0.108 + 0.105 + 0.008 + 0.008 = $0.23 Mil.
Total Current Assets was $1.13 Mil.
Total Assets was $4.11 Mil.
Property, Plant and Equipment(Net PPE) was $1.49 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.29 Mil.
Selling, General, & Admin. Expense(SGA) was $21.38 Mil.
Total Current Liabilities was $3.26 Mil.
Long-Term Debt & Capital Lease Obligation was $0.45 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.024 / 0.018) / (0.009 / 0.286)
=1.333333 / 0.031469
=42.3697

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(0.229 / 0.286) / (0.018 / 0.018)
=0.800699 / 1
=0.8007

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (0.528 + 0.938) / 1.798) / (1 - (1.128 + 1.49) / 4.11)
=0.18465 / 0.363017
=0.5087

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=0.018 / 0.286
=0.0629

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.293 / (0.293 + 1.49)) / (0.361 / (0.361 + 0.938))
=0.16433 / 0.277906
=0.5913

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(23.077 / 0.018) / (21.38 / 0.286)
=1282.055556 / 74.755245
=17.15

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0.103 + 4.582) / 1.798) / ((0.452 + 3.261) / 4.11)
=2.605673 / 0.903406
=2.8843

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-29.041 - -0.187 - -17.313) / 1.798
=-6.418799

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

BioSig Technologies has a M-score of 0.97 signals that the company is likely to be a manipulator.


BioSig Technologies Beneish M-Score Related Terms

Thank you for viewing the detailed overview of BioSig Technologies's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


BioSig Technologies (BioSig Technologies) Business Description

Traded in Other Exchanges
N/A
Address
55 Greens Farms Road, 1st Floor, Westport, CT, USA, 06880
BioSig Technologies Inc is a commercial stage medical device company. It is developing a proprietary technology platform to minimize noise and artifacts from cardiac recordings during electrophysiology studies and ablation.
Executives
Kenneth L Londoner director, 10 percent owner 10 RED COAT ROAD, WESTPORT CT 06880
Steven J Buhaly officer: Chief Financial Officer 1195 NW LOMPTON DRIVE, BEAVESTON OR 97006
John Sieckhaus officer: Chief Operating Officer C/O BIOSIG TECHNOLOGIES, 55 GREENS FARMS ROAD, WESTPORT CT 06880
Steve Chaussy officer: Chief Financial Officer 9780 E AVE, HESPERIA CA 92345
Patrick Joseph Gallagher director 275 PLEASANT HILL RD., FLANDERS NJ 07836
Gray Fleming officer: Chief Commercial Officer C/O BIOSIG TECHNOLOGIES, INC., 55 GREENS FARMS ROAD, WESTPORT CT 06880
James L Klein director 2300NE BROOKWOOD PKWY, HILLSBORO OR 97124
Frederick Hrkac director C/O BIOSIG TECHNOLOGIES, 55 GREENS FARMS ROAD, WESTPORT CT 06880
James J Barry director C/O INSPIREMD, INC., 4 MENORAT HAMAOR ST., TEL AVIV L3 6744832
Jeffrey F Odonnell director 126 ROSSMORE DRIVE, MALVERN PA 19355
Anthony P. Zook director C/O VIVUS, INC., 351 EAST EVELYN AVENUE, MOUNTAIN VIEW CA 94041
Jerome B Zeldis director 8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258
Martha Pease director 33 SEAVIEW, MADISON CT 06443
John M Kowalski officer: VP of Sales 54 WILTON ROAD, 2ND FLOOR, WESTPORT CT 06880
Samuel E Navarro director C/O STRATA SKIN SCIENCES, INC., 5 WALNUT GROVE DRIVE, SUITE 140, HORSHAM PA 19044